C-Ray Therapeutics

C-Ray Therapeutics is a global CRDMO (Contract Research, Development, and Manufacturing Organization) headquartered in Chengdu, China, dedicated to advancing the development and manufacturing of innovative radiopharmaceuticals. Founded in 2021, the company provides full-process, integrated services covering radiochemical process development, preclinical evaluation, IND-enabling studies, clinical supply, and commercial-scale cGMP production. Its 28,000 square meter R&D and production base includes automated hot cells, GLP-like non-clinical evaluation facilities, and Class A commercial manufacturing suites. C-Ray has completed over 100 CRDMO projects, including 58 preclinical and molecular imaging CRO projects and 42 CDMO projects, with pipeline assets advancing to Phase III clinical studies. The company has a particular strength in Ac-225-labeled radiopharmaceuticals and maintains a Radiopharmaceutical Innovation Ecosystem Alliance with partners including United Imaging and Grand Pharmaceutical Group. As of 2024, C-Ray had raised over $187 million in total funding, including a Series B of over $100 million.